Latest Rights Issue News

Halo Technologies Holdings Ltd posted a $17.4 million loss for 2025, widening from $14.5 million the previous year, as revenue fell 16%. The company completed a $3.9 million rights issue and announced a strategic pivot in its UK operations.

Activeport Group Ltd reported a 36% revenue decline and a 25% increase in net loss for the half-year ended December 2025, while securing key contracts with Tier 1 telcos and raising $8.8 million in capital.

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Eminence Minerals Limited has issued 2.7 million unquoted CEO performance rights as part of a new executive appointment, utilising its 15% placement capacity without shareholder approval.

Recharge Metals Limited has launched a pro-rata entitlement issue to raise $2.06 million, alongside a $3.97 million placement and a strategic acquisition of the Sunset Well Project in Western Australia. The capital raising aims to fund exploration and working capital, but shareholders face significant dilution and funding risks.

Recharge Metals Limited has inked a binding deal to acquire the Sunset Well Gold Project in Western Australia's Leonora district, featuring a 94,500-ounce inferred gold resource. The company has also secured $5.75 million in capital to kickstart drilling and exploration activities.

Identitii Limited has reopened its pro rata rights issue following a Takeovers Panel ruling, granting shareholders withdrawal rights and terminating the underwriting agreement.

Aquirian Limited has reported a strong rebound to profitability in the half year ending December 2025, driven by robust revenue growth and strategic partnerships that position it for expansion in mining services.

Identitii Limited faces a setback as Beauvais Capital terminates its underwriting agreement following Takeovers Panel orders, triggering shareholder withdrawal rights and uncertainty over the company’s capital raising plans.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.